Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "IMI"

4535 News Found

Artificial retinal device mimics human optical illusions: WPI-MANA
Biotech | March 10, 2022

Artificial retinal device mimics human optical illusions: WPI-MANA

The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte


Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Biotech | March 09, 2022

Alvotech settles with AbbVie to secure US rights to Humira biosimilar

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023


IOL Chemicals and Pharmaceuticals to limit capex at Rs 150 crore per year
News | March 07, 2022

IOL Chemicals and Pharmaceuticals to limit capex at Rs 150 crore per year

The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business


NATCO launches first generic version of Revlimid in the US
Drug Approval | March 07, 2022

NATCO launches first generic version of Revlimid in the US

NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene


Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers
Public Health | March 04, 2022

Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers

To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers


MIBCON NDC offers CO2 Optimisation module
Sustainability | March 04, 2022

MIBCON NDC offers CO2 Optimisation module

The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite


Limited impact of short-term disruptions, growth momentum to continue in FY 23
News | March 03, 2022

Limited impact of short-term disruptions, growth momentum to continue in FY 23

Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities


Amneal enters U.S. biosimilars market with approval of Releukotm
Drug Approval | March 02, 2022

Amneal enters U.S. biosimilars market with approval of Releukotm

First of three Amneal biosimilars expected for U.S. approval and launch in 2022


Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
News | February 28, 2022

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets


IMI releases tamper evident caps with DoseID certified RFID
Digitisation | February 26, 2022

IMI releases tamper evident caps with DoseID certified RFID

Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs